Table 1 Patients’ characteristics
From: PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma
Whole cohort (n = 146) | PFS24 cohort (n = 70, 50.4%) | noPFS24 cohort (n = 69, 49.6%) | p value | ||||||
|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||||
Age, median (range) | 60 (24–83) | 60.5 (24–83) | 61 (34–77) | 0.41 | |||||
> 65 years | 27 | 18.5 | 12 | 17.1 | 14 | 20.2 | 0.67 | ||
Sex, male | 86 | 58.9 | 41 | 58.5 | 41 | 59.4 | 0.53 | ||
Karnofsky PS < 70% | 40 | 27.4 | 14 | 20.0 | 25 | 36.2 | < 0.03 | ||
Elevated LDH | 67 | 47.9 | 30 | 43.4 | 36 | 54.5 | 0.15 | ||
n/a | 6 | 1 | 3 | ||||||
Elevated CSF protein | 78 | 76.5 | 40 | 69.0 | 35 | 83.3 | 0.16 | ||
n/a | 44 | 12 | 37 | ||||||
DBS | 89 | 60.1 | 44 | 62.8 | 39 | 56.5 | 0.49 | ||
ALC < 875/µL | 30 | 22.7 | 9 | 14.3 | 20 | 31.2 | 0.03 | ||
n/a | 14 | 7 | 5 | ||||||
High risk 3 F score | 17 | 12.9 | 3 | 4.8 | 14 | 21.9 | < 0.01 | ||
n/a | 14 | 7 | 5 | ||||||
High risk IELSG score | 30 | 29.1 | 19 | 33.3 | 14 | 29.2 | 0.83 | ||
n/a | 45 | 13 | 30 | ||||||
Dose reduction | 70 | 49.6 | 27 | 38.6 | 37 | 57.8 | 0.04 | ||
n/a | 5 | 5 | |||||||
Treatment | 0.27 | ||||||||
- MATRix | 111 | 76.0 | 52 | 78.3 | 54 | 80.8 | |||
- Freiburg protocol | 20 | 13.7 | 12 | 14.5 | 6 | 7.7 | |||
- MARTA | 15 | 10.3 | 6 | 7.2 | 9 | 11.5 | |||
HDC-AHSCT | 86 | 58.9 | 53 | 72.3 | 26 | 35.9 | < 0.001 | ||